Epidermal growth factor receptor mutations in lung cancer
作者： Sreenath V. Sharma , Daphne W. Bell , Jeffrey Settleman , Daniel A. Haber
DOI: 10.1038/NRC2088
关键词:
摘要: The development and clinical application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …
nature.com
sci-hub.se 参考文章(181)
Giuseppe Giaccone, Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 23, pp. 3235- 3242 ,(2005) , 10.1200/JCO.2005.08.409
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
Vu N. Ngo, R. Eric Davis, Laurence Lamy, Xin Yu, Hong Zhao, Georg Lenz, Lloyd T. Lam, Sandeep Dave, Liming Yang, John Powell, Louis M. Staudt, A loss-of-function RNA interference screen for molecular targets in cancer Nature. ,vol. 441, pp. 106- 110 ,(2006) , 10.1038/NATURE04687
Seungchan Yang, Shimian Qu, Marianela Perez-Tores, Ayana Sawai, Neal Rosen, David B. Solit, Carlos L. Arteaga, Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors Cancer Research. ,vol. 66, pp. 6990- 6997 ,(2006) , 10.1158/0008-5472.CAN-06-1042
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science. ,vol. 305, pp. 1163- 1167 ,(2004) , 10.1126/SCIENCE.1101637
Jie Ge, Emmanuel Normant, James R. Porter, Janid A. Ali, Marlene S. Dembski, Yun Gao, Asimina T. Georges, Louis Grenier, Roger H. Pak, Jon Patterson, Jens R. Sydor, Thomas T. Tibbitts, Jeffrey K. Tong, Julian Adams, Vito J. Palombella, Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Journal of Medicinal Chemistry. ,vol. 49, pp. 4606- 4615 ,(2006) , 10.1021/JM0603116
Masaki Tokumo, Shinichi Toyooka, Shuji Ichihara, Kadoaki Ohashi, Kazunori Tsukuda, Kouichi Ichimura, Masahiro Tabata, Katsuyuki Kiura, Motoi Aoe, Yoshifumi Sano, Hiroshi Date, Nobuyoshi Shimizu, Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer. ,vol. 53, pp. 117- 121 ,(2006) , 10.1016/J.LUNGCAN.2006.04.008
Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Na Zhang, Mika Savisalo, Pekka Mali, Jarmo Kulmala, Jaakko Pulkkinen, Reidar Grenman, Klaus Elenius, Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells Clinical Cancer Research. ,vol. 12, pp. 4103- 4111 ,(2006) , 10.1158/1078-0432.CCR-05-2404
Takeshi Shimamura, April M. Lowell, Jeffrey A. Engelman, Geoffrey I. Shapiro, Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research. ,vol. 65, pp. 6401- 6408 ,(2005) , 10.1158/0008-5472.CAN-05-0933
R Suzuki, , Y Hasegawa, K Baba, H Saka, H Saito, H Taniguchi, M Yamamoto, S Matsumoto, K Kato, T Oishi, K Imaizumi, K Shimokata, A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer British Journal of Cancer. ,vol. 94, pp. 1599- 1603 ,(2006) , 10.1038/SJ.BJC.6603159